Viewing Study NCT07016412

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:17 PM
Ignite Modification Date: 2025-12-26 @ 10:17 PM
Study NCT ID: NCT07016412
Status: RECRUITING
Last Update Posted: 2025-10-14
First Post: 2025-06-03
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Sponsor: Verona Pharma plc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Obstructive Pulmonary Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic Obstructive Pulmonary Disease View
None COPD View
None bronchodilator View
None ensifentrine-glycopyrrolate View